ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

June 13, 2011 7:00 AM UTC

Allergan Inc. (NYSE:AGN) lost $0.68 to $79.14 last week after the U.K.'s NICE recommended use of Ozurdex dexamethasone intravitreal implant to treat macular edema following central retinal vein occlusion (CRVO). NICE also recommended Ozurdex for macular edema following branch retinal vein occlusion (BRVO) when laser photocoagulation is not beneficial or suitable (see Online Links, A21).

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) lost $3.46 to $54.58 last week after partner Bayer AG (Xetra:BAY) submitted an MAA to EMA for VEGF Trap-Eye to treat wet age-related macular degeneration (AMD). A BLA from Regeneron has an Aug. 20 PDUFA date in the U.S. FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet on June 17 to discuss the application...